ENDRA Life Sciences announces 1-for-35 reverse stock split effective Nov 7, 2024

ENDRA Life Sciences Inc.

Board approved a ratio of 1/35 for the reverse stock split authorized by stockholders on Oct 28, 2024.
Amendment to Certificate of Incorporation filed with Delaware Secretary of State on Nov 4, 2024, effective 12:01 a.m. ET on Nov 7, 2024.
Common stock will trade on split-adjusted basis under new CUSIP 29273B 500 beginning Nov 7, 2024.
Each issued share of common stock will be reclassified and converted into 1/35 of a share.
No change to the par value of $0.0001 per share or the authorized number of shares.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ENDRA Life Sciences Inc.: Amendment to Certificate of Incorporation to effect a 1-for-35 reverse stock split (effective 2024-11-07).

Change: charter amendment
Effective: 2024-11-07

Exact text from the filing

On November 4, 2024, Company filed with the Secretary of State of the State of Delaware an amendment to the Certificate of Incorporation to effect the Reverse Stock Split (the “Amendment”) at 12:01 a.m. Eastern Time on November 7, 2024.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-013720

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.